CJC-1295 Half Life vs Ipamorelin PK Explained

What is the half life of CJC-1295?

CJC-1295 with DAC is long-acting, with a single injection producing sustained GH and IGF-1 elevations lasting several days in the human study most often cited (Teichman et al., 2006).

The reason is structural. CJC-1295 is a modified growth hormone releasing hormone (GHRH) analog. The DAC version adds a chemical group that binds covalently to circulating albumin. Albumin is one of the longest-lived proteins in the bloodstream, so tethering the peptide to it slows clearance dramatically. In the Teichman et al. (2006) trial published in the Journal of Clinical Endocrinology and Metabolism, single doses raised mean GH and IGF-1 and kept IGF-1 above baseline for an extended multi-day window rather than for hours.

That extended duration is the practical definition of "long half-life" for this compound. It is why research literature separates CJC-1295 with DAC from short-pulse secretagogues.

Note that a version of the molecule without DAC (sometimes labeled modified GRF 1-29) does not bind albumin and behaves as a much shorter-acting agent. The long half-life discussed here refers specifically to the DAC form.

How is ipamorelin different in pharmacokinetics?

Ipamorelin is short-acting and clears quickly compared with CJC-1295 with DAC, producing a brief GH pulse rather than a multi-day elevation (Raun et al., 1998).

Ipamorelin is not a GHRH analog. It is a selective growth hormone secretagogue that acts on the ghrelin receptor pathway to trigger GH release. In the foundational characterization by Raun et al. (1998) in the European Journal of Endocrinology, ipamorelin was shown to release GH selectively, without the rise in cortisol seen with some earlier secretagogues such as GHRP-6 and GHRP-2. That paper also reported that none of the secretagogues tested changed prolactin.

Because ipamorelin does not carry an albumin-binding component, it is described as short-acting. Detailed human half-life numbers are limited in the published record, so a single confident figure is hard to defend from the primary literature. The honest summary: ipamorelin drives a short pulse and is cleared far faster than the DAC form of CJC-1295.

Why are CJC-1295 and ipamorelin discussed together?

They are paired in research discussion because they work through two separate mechanisms, one long-acting and one short-pulse, and researchers study the contrast.

CJC-1295 with DAC acts on the GHRH receptor and raises the baseline of GH signaling over days. Ipamorelin acts on the ghrelin/secretagogue receptor and adds a sharp, short pulse. Because the mechanisms differ, the compounds are frequently examined side by side in the secretagogue literature. This does not mean the two should be combined by any reader. Any combination question is a clinical decision, not a self-directed one.

PK comparison at a glance

The table summarizes what the cited sources report about each compound. Values that are not well established in the human literature are marked as limited rather than filled with an unverified number.

What doses did the research use?

This section reports what published studies administered and is not guidance for any reader.

In the Teichman et al. (2006) study, participants received single subcutaneous doses of CJC-1295 across defined ranges to characterize the GH and IGF-1 response, and the sustained multi-day elevation described above followed those single doses. Raun et al. (1998) characterized ipamorelin's GH-releasing profile in a research setting rather than as a treatment protocol.

Neither trial establishes a dose for a reader to use. Any personal dose, schedule, or decision to use these compounds at all is a matter for a qualified clinician who can weigh individual context.